BRIEF published on 08/13/2026 at 07:35, 2 months 22 days ago Ottobock Reports Revenue Increase and Margin Improvement Revenue Growth EBITDA Margin Organic Growth Strategic Acquisitions Market Expansion
PRESS RELEASE published on 08/13/2026 at 07:30, 2 months 22 days ago Ottobock strongly increases revenue in the first half of the year and significantly improves its margin Ottobock SE & Co. KGaA reports strong revenue increase and margin improvement in H1 2026, driven by organic growth and strategic investments Revenue Increase Organic Growth Margin Improvement Ottobock H1 2026
BRIEF published on 07/13/2026 at 10:05, 3 months 22 days ago Ottobock Launches Dynion Explore Prosthetic Knee for Adolescents Global Rollout Prosthetic Development Adolescent Mobility Hydraulic Knee Joint Active Lifestyle Support
PRESS RELEASE published on 07/13/2026 at 10:00, 3 months 22 days ago dynion explore: new prosthetic knee joint for adolescents. Ottobock introduces dynion explore, a new prosthetic knee joint for active adolescents and adults with low body weight, closing treatment gap. Global launch in Europe, US, and China Ottobock Adolescents Dynion Explore Prosthetic Knee Joint Treatment Gap
BRIEF published on 07/07/2026 at 07:35, 3 months 28 days ago Ottobock Expands Neuro-Orthotics Portfolio with Strategic Acquisition Acquisition Ottobock Neuro-Orthotics Fesia Technology Functional Electrical Stimulation
PRESS RELEASE published on 07/07/2026 at 07:30, 3 months 28 days ago Ottobock continues strategic expansion of Neuro-Orthotics with acquisition Ottobock acquires Fesia Technology, S.L. to expand Neuro-Orthotics portfolio with Functional Electrical Stimulation products for neurological conditions Acquisition Ottobock Neuro-Orthotics Fesia Technology Functional Electrical Stimulation
BRIEF published on 06/24/2026 at 11:35, 4 months 10 days ago Ottobock Welcomes Dr. Katarzyna Mazur-Hofsaess to Management Board Board Appointment MedTech Leadership Change Ottobock Healthcare Expertise
PRESS RELEASE published on 06/24/2026 at 11:30, 4 months 10 days ago Ottobock appoints Dr. Katarzyna Mazur-Hofsaess to the Management Board Ottobock appoints Dr. Katarzyna Mazur-Hofsaess to the Management Board, succeeding Stefan Heidenreich. Dr. Mazur-Hofsaess brings international experience in medical technology and healthcare Medical Technology Management Board Ottobock Dr. Katarzyna Mazur-Hofsaess Stefan Heidenreich
BRIEF published on 06/19/2026 at 11:35, 4 months 15 days ago Ottobock Sells Human Mobility Wheelchair Division Strategic Focus Mobility Solutions Ottobock DHCare Wheelchair Business
PRESS RELEASE published on 06/19/2026 at 11:30, 4 months 15 days ago Ottobock sells its Human Mobility wheelchair business Ottobock SE & Co. KGaA sells its Human Mobility wheelchair business to DHCare, focusing on core areas for growth. Transaction expected to close in H2/2026 Strategic Focus MedTech Ottobock DHCare Wheelchair Business
Published on 11/04/2026 at 23:10, 4 hours 14 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 4 hours 24 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 5 hours 9 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 5 hours 19 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/05/2026 at 03:10, 14 minutes ago SensAI Veritas Launches SensAI Gateway™ and SensAI Helm™: Bringing Risk Intelligence to the Moment of Trust
Published on 11/05/2026 at 00:02, 3 hours 22 minutes ago EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 7 hours 43 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 7 hours 59 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 8 hours 41 minutes ago EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:00, 9 hours 24 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 17:44, 9 hours 40 minutes ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
Published on 11/04/2026 at 11:56, 15 hours 27 minutes ago Mersen: Number of shares and voting rights as of October 31, 2026
